Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors

F. Meric-Bernstam; H. Arkenau; B. Tran; R. Bahleda; R. Kelley; C. Hierro; D. Ahn; A. Zhu; M. Javle; R. Winkler; H. He; J. Huang; L. Goyal

doi:10.1093/annonc/mdy149

Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors

F. Meric-Bernstam, H. Arkenau, B. Tran, R. Bahleda, R. Kelley, C. Hierro, D. Ahn, A. Zhu, M. Javle, R. Winkler, H. He, J. Huang, L. Goyal

Hematology/Oncology

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	v100
Journal	Annals of oncology : official journal of the European Society for Medical Oncology
Volume	29
DOIs	https://doi.org/10.1093/annonc/mdy149
State	Published - Jun 1 2018

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdy149

Cite this

Meric-Bernstam, F., Arkenau, H., Tran, B., Bahleda, R., Kelley, R., Hierro, C., Ahn, D., Zhu, A., Javle, M., Winkler, R., He, H., Huang, J., & Goyal, L. (2018). Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors. Annals of oncology : official journal of the European Society for Medical Oncology, 29, v100. https://doi.org/10.1093/annonc/mdy149

Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors. / Meric-Bernstam, F.; Arkenau, H.; Tran, B. et al.
In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, 01.06.2018, p. v100.

Research output: Contribution to journal › Article › peer-review

Meric-Bernstam, F, Arkenau, H, Tran, B, Bahleda, R, Kelley, R, Hierro, C, Ahn, D, Zhu, A, Javle, M, Winkler, R, He, H, Huang, J & Goyal, L 2018, 'Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, pp. v100. https://doi.org/10.1093/annonc/mdy149

Meric-Bernstam F, Arkenau H, Tran B, Bahleda R, Kelley R, Hierro C et al. Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Jun 1;29:v100. doi: 10.1093/annonc/mdy149

Meric-Bernstam, F. ; Arkenau, H. ; Tran, B. et al. / Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors. In: Annals of oncology : official journal of the European Society for Medical Oncology. 2018 ; Vol. 29. pp. v100.

@article{213af17122a84426959f99bfd17f3308,

title = "Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors",

author = "F. Meric-Bernstam and H. Arkenau and B. Tran and R. Bahleda and R. Kelley and C. Hierro and D. Ahn and A. Zhu and M. Javle and R. Winkler and H. He and J. Huang and L. Goyal",

year = "2018",

month = jun,

day = "1",

doi = "10.1093/annonc/mdy149",

language = "English (US)",

volume = "29",

pages = "v100",

journal = "Annals of oncology : official journal of the European Society for Medical Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors

AU - Meric-Bernstam, F.

AU - Arkenau, H.

AU - Tran, B.

AU - Bahleda, R.

AU - Kelley, R.

AU - Hierro, C.

AU - Ahn, D.

AU - Zhu, A.

AU - Javle, M.

AU - Winkler, R.

AU - He, H.

AU - Huang, J.

AU - Goyal, L.

PY - 2018/6/1

Y1 - 2018/6/1

UR - http://www.scopus.com/inward/record.url?scp=85065095625&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065095625&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy149

DO - 10.1093/annonc/mdy149

M3 - Article

C2 - 32176980

SN - 0923-7534

VL - 29

SP - v100

JO - Annals of oncology : official journal of the European Society for Medical Oncology

JF - Annals of oncology : official journal of the European Society for Medical Oncology

ER -

Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this